| ||||||||||||||
|
|
|||||||||||||
Department of Psychology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Address correspondence to Drake Morgan, Center for the Neurobiological Investigation of Drug Abuse, Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Medical Center Blvd., Winston Salem, NC 27157.
We examined the effects of several opioids that vary in intrinsic efficacy at the µ-opioid receptor alone and in combination with morphine in a rat warm water tail withdrawal procedure using 50°C and 52°C water (i.e., low- and high-stimulus intensities). Morphine, levorphanol, dezocine, and buprenorphine produced dose-dependent increases in antinociception using both stimulus intensities. Butorphanol produced maximal levels of antinociception at the low, but not at the high, stimulus intensity, whereas nalbuphine failed to produce antinociception at either stimulus intensity. For cases in which butorphanol and nalbuphine failed to produce antinociception alone, these opioids dose-dependently antagonized the effects of morphine. When levorphanol, dezocine, and buprenorphine were combined with morphine, there was a dose-dependent enhancement of morphine's effects. Similar effects were obtained at the low-stimulus intensity when butorphanol was administered with morphine. In most cases, the effects of these combinations could be predicted by summating the effects of the drugs when administered alone. These results indicate that the level of antinociception produced by an opioid is dependent on the intrinsic efficacy of the drug and the stimulus intensity. Furthermore, the level of antinociception produced by the opioid, not necessarily the opioids' intrinsic efficacy, determines the type of interaction among opioids.
Implications: Compared with high-efficacy opioids, lower efficacy opioids produce lower levels of pain relief, especially in situations of moderate to severe pain. When opioids are given in combination, the effects can only be predicted on the basis of the antinociception obtained when the drugs are administered alone.
This article has been cited by other articles:
![]() |
B. D. Fischer and L. A. Dykstra Interactions between an N-Methyl-D-aspartate Antagonist and Low-Efficacy Opioid Receptor Agonists in Assays of Schedule-Controlled Responding and Thermal Nociception J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1300 - 1306. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Comer, M. A. Sullivan, and E. A. Walker Comparison of Intravenous Buprenorphine and Methadone Self-Administration by Recently Detoxified Heroin-Dependent Individuals J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1320 - 1330. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. Cook and M. D. Nickerson Nociceptive Sensitivity and Opioid Antinociception and Antihyperalgesia in Freund's Adjuvant-Induced Arthritic Male and Female Rats J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 449 - 459. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Allen, A. L. Granger, and L. A. Dykstra The Competitive N-Methyl-D-aspartate Receptor Antagonist (-)-6-Phosphonomethyl-deca-hydroisoquinoline-3-carboxylic Acid (LY235959) Potentiates the Antinociceptive Effects of Opioids That Vary in Efficacy at the {micro}-Opioid Receptor J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 785 - 792. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Rowbotham, L. Twilling, P. S. Davies, L. Reisner, K. Taylor, and D. Mohr Oral Opioid Therapy for Chronic Peripheral and Central Neuropathic Pain N. Engl. J. Med., March 27, 2003; 348(13): 1223 - 1232. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Allen and L. A. Dykstra Attenuation of {micro}-Opioid Tolerance and Cross-Tolerance by the Competitive N-Methyl-D-aspartate Receptor Antagonist LY235959 Is Related to Tolerance and Cross-Tolerance Magnitude J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 1012 - 1021. [Abstract] [Full Text] |
||||
![]() |
D. Morgan, C. D. Cook, and M. J. Picker Sensitivity to the Discriminative Stimulus and Antinociceptive Effects of µ Opioids: Role of Strain of Rat, Stimulus Intensity, and Intrinsic Efficacy at the µ Opioid Receptor J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 965 - 975. [Abstract] [Full Text] |
||||
|